Key Points
- Maze Therapeutics insider Atul Dandekar sold 7,500 shares at an average price of $27.06, generating $202,950. The sale, conducted under a pre-arranged Rule 10b5-1 plan, reduced his holdings by 18.84% to 32,316 shares.
- MAZE shares opened at $26.65 and have declined 1.9%, with the stock trading below its 50-day and 200-day moving averages. The company reported a quarterly loss of $0.76 per share, while analysts expect a full-year loss of $2.72 per share.
- Analyst sentiment remains mixed but leans positive: the stock carries a consensus “Buy” rating and a $63.40 target price, despite recent sell ratings. Several major institutional investors, including Frazier Life Sciences Management, BlackRock, and ARCH Venture Management, recently increased or initiated positions.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of the business's stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $27.06, for a total transaction of $202,950.00. Following the sale, the insider owned 32,316 shares of the company's stock, valued at approximately $874,470.96. This represents a 18.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Atul Dandekar also recently made the following trade(s):
- On Thursday, September 3rd, Atul Dandekar sold 3,243 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total transaction of $84,350.43.
- On Wednesday, September 2nd, Atul Dandekar sold 3,191 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total transaction of $84,465.77.
- On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.58, for a total transaction of $206,850.00.
- On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00.
Maze Therapeutics Stock Down 1.9%
Shares of NASDAQ MAZE opened at $26.65 on Friday. The stock has a fifty day moving average price of $27.00 and a 200 day moving average price of $28.23. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics, Inc. has a 12-month low of $21.95 and a 12-month high of $53.65. The company has a market cap of $1.48 billion, a P/E ratio of -10.58 and a beta of 2.16.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting analysts' consensus estimates of ($0.76). Research analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
MAZE has been the topic of several recent research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Monday, September 21st. BTIG Research reaffirmed a "buy" rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Wall Street Zen lowered shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Citigroup began coverage on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. They set a "buy" rating and a $50.00 target price on the stock. Finally, TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $63.40.
Read Our Latest Research Report on MAZE
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the business. Frazier Life Sciences Management L.P. grew its stake in Maze Therapeutics by 10.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company's stock valued at $150,182,000 after purchasing an additional 465,641 shares in the last quarter. TRV GP IV LLC purchased a new stake in Maze Therapeutics during the 2nd quarter worth approximately $133,502,907. ARCH Venture Management LLC acquired a new position in shares of Maze Therapeutics in the 2nd quarter valued at approximately $122,983,582. BlackRock Inc. acquired a new position in shares of Maze Therapeutics in the 2nd quarter valued at approximately $104,525,000. Finally, Jupiter Topco LLC purchased a new position in shares of Maze Therapeutics during the 2nd quarter valued at approximately $101,764,000.
Maze Therapeutics Company Profile
(
Get Free Report)
Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.
Maze's pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
